

This article was downloaded by:

On: 27 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

Synthesis and Cytostatic Activity of Halomethylthiazole C-Nucleosides and Analogues¹

M. Teresa García-López^a; Rosario Herranz^a; Paloma P. Méndez-Castrillón^a

^a Institute de Química Médica, Spain

To cite this Article García-López, M. Teresa , Herranz, Rosario and Méndez-Castrillón, Paloma P.(1982) 'Synthesis and Cytostatic Activity of Halomethylthiazole C-Nucleosides and Analogues', *Nucleosides, Nucleotides and Nucleic Acids*, 1: 2, 127 – 138

To link to this Article: DOI: 10.1080/07328318208078827

URL: <http://dx.doi.org/10.1080/07328318208078827>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

SYNTHESIS AND CYTOSTATIC ACTIVITY OF
HALOMETHYLTHIAZOLE C-NUCLEOSIDES AND ANALOGUES¹

M^a Teresa García-López *, Rosario Herranz and
Paloma P. Méndez-Castrillón

Instituto de Química Médica. Juan de la Cierva 3. Madrid-6. Spain.


Abstract. The synthesis of 2-(β -D-ribofuranosyl)- and 2-(tetrahydropyran-2-yl)-4-halomethylthiazoles from 2,5-anhydro-D-allonothioamide and tetrahydropyran-2-thiocarboxamide is described. Bromination of 2-(β -D-ribofuranosyl)- and 2-tetrahydropyran-2-yl)-4-methylthiazole with NBS is studied. Cytostatic activity against HeLa cells of all the compounds is reported.

With the aim of exploring the possibilities of benzylic type halides as a new type of cytotoxic alkylating agents, we have reported the synthesis, cytostatic activity and mode of action of a series of N-glycosyl derivatives of several halomethylpentaheterocycles². Studies on structure-activity relationships demonstrated that the presence of the glycosyl moiety is required for cytostatic activity, although the nature of such moiety does not seem to be determinant of activity^{2,3,4}. Due to these facts, we considered of interest, in one hand, to prepare C-ribosyl halomethyl heterocycles in order to increase the strenght of the sugar-aglycon bond, and, on the other, to compare their activities with those of the corresponding tetrahydropyranyl derivatives, considering tetrahydropyran as a simple model of sugars.

The present paper describes the synthesis of 2-(β -D-ribofuranosyl)- and 2-(tetrahydropyran-2-yl)-4-halomethylthiazoles. It also describes the study of the bromination of 2-(β -D-ribofuranosyl)- and 2-(tetrahydropyran-2-yl)-4-methylthiazole with N-bromosuccinimide.

The procedure reported in the literature for the preparation of 2-glycosyl thiazoles involves the condensation of hydroxyl protected glycosylthiocarboxamides with α -halocarbonyl compounds^{5,6}. In those cases the use of 2,5-anhydro-3,4,6-tri-O-benzoyl-D-allonothioamide afforded, besides the desired 2-(2,3,5-tri-O-benzoyl- β -D-ribofuranosyl)thiazoles, 2-(5-benzoyloxymethylfuran-2-yl)thiazoles resulting from benzoate elimination. In order to avoid such elimination during cyclization reaction, 2,5-anhydro-3,4-O-isopropylidene-D-allonothioamide and 2,5-anhydro-6-O-benzoyl-D-allonothioamide were used in those reactions^{5a,6}. In our case, 2,5-anhydro-D-allonothioamide (2) was utilized as the starting material which was readily obtained as the only reaction product in 87% yield when β -D-ribofuranosyl cyanide (1) was treated with hydrogen sulfide in the presence of triethylamine. Reaction of the thioamide 2 with 1,3-dichloroacetone or 1,3-dibromoacetone in ethanol afforded 2-(β -D-ribofuranosyl)-4-chloromethylthiazole (3) or 2-(β -D-ribofuranosyl)-4-bromomethylthiazole (4) in 38 and 25% yield, respectively. It is interesting to note that the use of the hydroxyl deprotected thioamide 2 in the preparation of the halomethylthiazoles 3 and 4 has allowed us to obtain for the first time, deprotected alkylating nucleosides, since all the attempts to remove the sugar hydroxyl protecting groups in the series of N-glycosyl halomethyl heterocycles were unsuccessful^{4,7}.


Similar condensation reactions of tetrahydropyran-2-thiocarboxamide (5), obtained in 90% yield from 2-cyanotetrahydropyran⁸, with 1,3-dichloroacetone or 1,3-dibromoacetone gave 2-(tetrahydropyran-2-yl)-4-chloromethylthiazole (6) or 2-(tetrahydropyran-2-yl)-4-bromomethylthiazole (7) in 55 and 26% yield respectively.




Iodomethylthiazole derivatives, namely 2-(β -D-ribofuranosyl)- and 2-(tetrahydropyran-2-yl)-4-iodomethylthiazole (8 and 9) were obtained from the corresponding chloromethyl analogs 3 and 6 by transhalogenation reaction with sodium iodide in acetone.

Pure samples of the ribofuranosyl derivatives 3, 4 and 8 were obtained when recently purified by TLC. However, these compounds, specially the chloro- and the bromomethyl substituted nucleosides 3 and 4, obtained as syrups decomposed on standing.

In order to explore an alternative procedure for the preparation of the bromomethylthiazoles 4 and 7, we attempted a route which had been successfully used in the synthesis of certain N-glycosyl bromo-



methylpyrazoles ⁹ and N-glycosyl bromomethylimidazoles ¹⁰. This route consists on the generation of the bromomethyl group on methyl substituted nucleosides, previously formed. With this end, the thioamides 2 and 5 were condensed with chloroacetone to give 2-(β -D-ribofuranosyl)-4-methylthiazole ^{5a} (10) and 2-(tetrahydropyran-2-yl)-4-methylthiazole (11) in 40 and 44% yield, respectively. It should be noted that compound 10 has been previously prepared by debenzoylation of 2-(2,3,5-tri-O-benzoyl- β -D-ribofuranosyl)-4-methylthiazole, obtained by reaction of 2,5-anhydro-3,4,6-tri-O-benzoyl-D-allon-thioamide with chloroacetone. That condensation reaction also led to 2-(5-benzoyloxymethylfuran-2-yl)-4-methylthiazole resulting from elimination of two benzyloxy groups. As mentioned before, the use of the unprotected thiocarboxamide 2 has allowed us to avoid the easy benzoate elimination during cyclization and to prepare the methylthiazole 10 in one step and in higher yield than that reported ^{5a}. Reaction of methylthiazoles 10 and 11 with N-bromosuccinimide, irradiating with a 200 wat lamp, provided 2-(β -D-ribofuranosyl)-5-bromo-4-methylthiazole (12) and 2-(tetrahydropyran-2-yl)-5-bromo-4-methylthiazole (13), respectively, as the only reaction products.



The absence of the signal corresponding to the H-5 thiazole proton and the presence of the signal corresponding to CH_3 -4 in the ^1H NMR spectra of 12 and 13 clearly demonstrated that bromination took place at C-5 of the thiazole ring. (TABLE 1).

All the compounds reported in this paper were evaluated as cytotoxic agents against HeLa cell cultures¹¹. Although the cytostatic activity was associated with the presence of the alkylating halomethyl group, only the bromomethyl and iodomethyl derivatives 7 and 9 showed significant activity. The activities of the 2-(β -D-ribofuranosyl) halomethylthiazoles 3, 4 and 8 were not significant (3 and 4: $\text{ID}_{50} = 10$ -100 $\mu\text{g}/\text{ml}$; 8: $\text{ID}_{50} = 10$ $\mu\text{g}/\text{ml}$) and, in all cases, lower than those of the corresponding tetrahydropyranyl derivatives 6, 7 and 9 ($\text{ID}_{50} = 10$, 5 and 4 $\mu\text{g}/\text{ml}$, respectively). The low activity of ribofuranosyl derivatives 3, 4 and 8 may be due to their instability.

TABLE 1. Chemical shift (δ) and coupling constants (Hz) of 2-(β -D-ribofuranosyl)- and 2-(tetrahydropyran-2-yl)-thiazoles.

No	Solvent	H-5	H-1' ^{a)}	CH ₂ X	J _{1', 2'} ^{a)}
			H-2' ^{b)}		J _{2'a, 3'a} + J _{2'a, 3'e} ^{b)}
<u>3</u>	DMSO + D ₂ O	7.83	5.03	4.90 (X = Cl)	5.5
<u>4</u>	DMSO + D ₂ O	7.83	4.98	4.78 (X = Br)	4.5
<u>6</u>	DMSO	7.38	4.70	4.83 (X = Cl)	11
<u>7</u>	CDCl ₃	7.35	4.70	4.62 (X = Br)	11
<u>8</u>	DMSO + D ₂ O	7.55	4.98	4.55 (X = I)	4
<u>9</u>	CDCl ₃	7.28	4.70	4.55 (X = I)	12
<u>10</u>	DMSO + D ₂ O	7.30	4.95	2.38 (X = H)	5
<u>11</u>	DMSO	7.24	4.68	2.36 (X = H)	12
<u>12</u>	DMSO + D ₂ O	--	4.92	2.35 (X = H)	5
<u>13</u>	DMSO	--	4.65	2.32 (X = H)	11

a) β -D-Ribofuranosyl derivatives

b) Tetrahydropyranyl derivatives.

EXPERIMENTAL

Melting points were determined on a Kofler hot-stage apparatus and are uncorrected. Proton nuclear magnetic resonance spectra were recorded at 60 MHz with a Perkin-Elmer R-12 spectrometer using Me₄Si as internal standard. Analytical thin layer chromatography was performed on aluminium sheets coated with a 0.02 mm layer of silica gel 60 F₂₅₄ (Merck). Preparative layer chromatography was performed on 20 x 20 cm glass plates coated with a 2 mm layer of silica gel PF₂₅₄ (Merck). Compounds were detected with UV light (254 nm) or by spraying the plate with a ethanol-sulfuric acid (7:3) mixture and heat-

ing. Column chromatography was performed on glass columns filled with silica gel 60, 70-230 mesh (Merck).

β -D-Ribofuranosyl cyanide (1). A solution of 2,3,5-tri-O-benzoyl- β -D-ribofuranosyl cyanide¹² (4.67 g, 1.07 mmole) in saturated methanolic ammonia (250 mL) was allowed to stand at room temperature for 24 h. The residue obtained by evaporation of the solvent was chromatographed on a silica gel column. Elution with CHCl_3 -acetone (9:1) and then with acetone furnished 1.23 g (78.5%) of 1 as a syrup which solidified on standing, mp 91-93°C; NMR ($\text{DMSO}-\text{D}_2\text{O}$): δ 4.46 (d, 1, $J_{1,2} = 2.5$ Hz, H-1).

Anal. Calcd. for $\text{C}_6\text{H}_9\text{NO}_4$: C, 45.28; H, 5.70; N, 8.80. Found: C, 44.94; H, 5.63; N, 9.20.

2,5-Anhydro-D-allonthioamide (2). Hydrogen sulfide was bubbled into a solution of 1 (1.23 g, 7.73 mmole) in ethanol (50 mL) containing triethylamine (0.90 mL) for 2 h. The solvent was evaporated and the residue was purified by preparative TLC using acetone- CHCl_3 (1:1). Elution of the major band afforded 1.30 g (87.5%) of 2, mp 116°C (from 2-propanol); NMR ($\text{DMSO}-\text{D}_2\text{O}$): δ 4.40 (d, 1, $J_{2,3} = 2$ Hz, H-2).

Anal. Calcd. for $\text{C}_6\text{H}_{11}\text{NO}_4\text{S}$: C, 37.30; H, 5.74; N, 7.25; S, 16.56. Found: C, 37.58; H, 6.06; N, 7.29; S, 16.20.

2-(β -D-Ribofuranosyl)-4-chloromethylthiazole (3). A solution of 2 (0.29 g, 1.50 mmole) and 1,3-dichloroacetone (0.189 g, 1.5 mmole) in ethanol (25 mL) was heated under reflux for 8 h. The solvent was removed and the residue was purified by preparative TLC using CHCl_3 -MeOH (9:1). Elution of the major band gave 3 (0.15 g, 38%) as a homogeneous syrup.

Anal. Calcd. for $\text{C}_9\text{H}_{12}\text{ClNO}_4\text{S}$: C, 40.70; H, 4.55; N, 5.27; S, 12.05. Found: C, 41.04; H, 4.73; N, 4.89; S, 11.89.

2-(β -D-Ribofuranosyl)-4-bromomethylthiazole (4). A solution of 2 (1.00 g, 4.60 mmole) and 1,3-dibromoacetone (1.10 g, 5.10 mmole) in ethanol (50 mL) was heated under reflux for 1 h. The solvent was evaporated to provide a syrup which was chromatographed by preparative TLC using CHCl_3 -MeOH (9:1). Elution of the major band gave 4 (0.40 g, 25%) as a homogeneous syrup.

Anal. Calcd. for $\text{C}_9\text{H}_{12}\text{BrNO}_4\text{S}$: C, 34.84; H, 3.89; N, 4.51; S, 10.31. Found: C, 34.43; H, 3.56; N, 4.71; S, 9.98.

Tetrahydropyran-2-thiocarboxamide (5). A mixture of 2-cyanotetrahydropyran⁸ (12.24 g, 0.13 mmole), triethylamine (3.5 mL) and ethanol (60 mL) was stirred at room temperature for 2 h., while hydrogen sulfide was bubbled into the solution. Evaporation of the solvent left a solid which was recrystallized from EtOH to give 5 (12.8 g, 90%) mp 120°C; NMR (CDCl_3): δ 4.20 (dd, 1, $J_{2a,3a}$ = 10 Hz; $J_{2a,3e}$ = 2 Hz, H-2).

Anal. Calcd. for $\text{C}_6\text{H}_{11}\text{NOS}$: C, 49.64; H, 7.63; N, 9.65; S, 22.04. Found: C, 49.83; H, 7.51; N, 10.10; S, 22.22.

2-(Tetrahydropyran-2-yl)-4-chloromethylthiazole (6). A solution of 5 (1.45 g, 10 mmole) and 1,3-dichloroacetone (1.27 g, 10 mmole) in ethanol (25 mL) was refluxed for 1 h. The solvent was evaporated and the residue was purified by preparative TLC using CHCl_3 . Elution of the major band gave 6 (1.2 g, 55%), mp 91-92°C (from EtOH).

Anal. Calcd. for $\text{C}_9\text{H}_{12}\text{ClNOS}$: C, 49.68; H, 5.55; N, 6.43; S, 14.70. Found: C, 49.81; H, 5.85; N, 6.79; S, 14.99.

2-(Tetrahydropyran-2-yl)-4-bromomethylthiazole (7). 1,3-Dibromoacetone (2.16 g, 10 mmole) was slowly added to a solution of 5 (1.45 g, 10 mmole) in ethanol (25 mL) at room temperature. Then, the solvent was removed and the residue was chromatographed by preparative TLC using CHCl_3 -hexane (4:1). Elution of the major

band afforded a solid which was recrystallized from cyclohexane to give 7 (0.34 g, 26%), mp 89-91°C.

Anal. Calcd. for $C_9H_{12}BrNOS$: C, 41.22; H, 4.61; N, 5.34; S, 12.20. Found: C, 41.44; H, 4.90; N, 5.49; S, 12.31.

2-(β -D-Ribofuranosyl)-4-iodomethylthiazole (8). A solution of 3 (0.36 g, 1.35 mmole) and NaI (0.30 g, 2 mmole) in dry acetone (50 mL) was heated under reflux until a precipitate of NaCl formed (~5 min). After cooling, the NaCl was removed by filtration and washed with dry acetone. The filtrate and washing were evaporated, and the residue chromatographed by preparative TLC using $CHCl_3$ -MeOH (9:1). Elution of the major band gave 8 (0.30 g, 26%) as a syrup which solidified on standing, mp 83-85°C.

Anal. Calcd. for $C_9H_{12}INO_4S$: C, 30.27; H, 3.38; N, 3.92; S, 8.96. Found: C, 30.66; H, 3.55; N, 4.00; S, 8.77.

2-(Tetrahydropyran-2-yl)-4-iodomethylthiazole (9). A solution of 6 (0.60 g, 2.75 mmole) and NaI (0.82 g, 5.46 mmole) in dry acetone (40 mL) was heated under reflux until a precipitate of NaCl formed (~2 min). After cooling, the NaCl was removed by filtration and washed with dry acetone. The filtrate and washing were evaporated. The residue was treated with a saturated solution of sodium thiosulfate and extracted with EtOAc (50 mL). The organic layer was washed with H_2O and dried over Na_2SO_4 . Evaporation of the solvent left a yellow syrup which was chromatographed by preparative TLC using $CHCl_3$ -hexane (2:1). Elution of the major band yielded 9 (0.54 g, 64%), mp 54-55°C (from cyclohexane).

Anal. Calcd. for $C_9H_{12}INOS$: C, 34.95; H, 3.88; N, 4.53; S, 10.35. Found: C, 35.10; H, 4.15; N, 4.80; S, 10.20.

2-(β -D-Ribofuranosyl)-4-methylthiazole (10). A solution of 2 (0.64 g, 3.3 mmole) and chloroacetone (0.30 g, 3.3 mmole) in ethanol (30 mL) was refluxed for 8 h. The solvent was evaporated

and the residue purified by preparative TLC using CHCl_3 -MeOH (9:1). Elution of the major band gave 10 (0.30 g, 40%), mp 122-123° C (from EtOAc-petroleum ether) (lit.⁵ mp 122-124° C).

2-(Tetrahydropyran-2-yl)-4-methylthiazole (11). A solution of 5 (2 g, 13.8 mmole) and chloroacetone (1.27 g, 13.8 mmole) in ethanol (50 mL) was refluxed for 5 h. Evaporation of the solvent left a residue which was dissolved in H_2O (10 mL) and neutralized with NaHCO_3 . This was extracted with EtOAc (25 mL x 2); the organic portion was washed with H_2O and dried over Na_2SO_4 . Evaporation of the solvent provided 2 g of a chromatographically homogeneous syrup from which an analytically pure sample could not be obtained. Then, hydrogen chloride was bubbled into a solution of the syrup in ether (60 mL). The precipitated solid was collected by filtration to give pure 11 as its hydrochloride (1.34 g, 44%), mp 108-110° C (from EtOAc).

Anal. Calcd. for $\text{C}_9\text{H}_{13}\text{NOS} \cdot \text{HCl} \cdot \frac{1}{2} \text{H}_2\text{O}$: C, 47.26; H, 6.56; N, 16.12; S, 14.00. Found: C, 47.66; H, 6.77; N, 6.09; S, 14.04.

2-(β -D-Ribofuranosyl)-5-bromo-4-methylthiazole (12). To a solution of 10 (46 mg, 0.20 mmole) in methanol (30 mL) was added N-bromosuccinimide (72 mg, 0.40 mmole) and the mixture was irradiated for 20 min by suspending the flask one centimeter above a 200 watt lamp. Evaporation of the solvent left a residue which was purified by preparative TLC, using CHCl_3 -acetone (1:1) to give 12 (42 mg, 68%), mp 167° C (from acetone).

Anal. Calcd. for $\text{C}_9\text{H}_{12}\text{BrNO}_4\text{S}$: C, 34.84; H, 3.89; N, 4.51; S, 10.31. Found: C, 34.89; H, 3.81; N, 4.52; S, 10.68.

2-(Tetrahydropyran-2-yl)-5-bromo-4-methylthiazole (13). To a solution of 11 (1.44 g, 7.8 mmole) in methanol (50 mL) was added N-bromosuccinimide (2.77 g, 15.6 mmole) and the mixture was irradiated for 15 min as it indicated above. Evaporation of the solvent left a residue which was purified by preparative TLC using EtOAc-

hexane (1:2) to give 13 (0.76 g, 37%) as a syrup which solidified on standing, mp 37-38°C.

Anal. Calcd. for $C_9H_{12}BrNOS$: C, 41.22; H, 4.61; N, 5.34; S, 12.20. Found: C, 40.91; H, 4.81; N, 5.36; S, 11.80.

ACKNOWLEDGMENTS

The authors thanks Mrs. Emilia Bayo for technical assistance. We also thank the Comisión Asesora de Investigación Científica y Técnica for financial support and the Fundación Científica de la Asociación Española contra el Cáncer for a Fellowship.

REFERENCES

1. Paper nº 9 in the "Alkylating nucleosides".
2. M.T. García-López and F.G. de las Heras in "Medicinal Chemistry Advances", F.G. de las Heras and S. Vega, Eds. Pergamon Press, Oxford and New York, 1981, p. 69.
3. M.T. García-López, R. Herranz and G. Alonso, J. Med. Chem., **22**, 807 (1979).
4. R. Alonso, M.J. Camarasa, G. Alonso and F.G. de las Heras, Eur. J. Med. Chem., **15**, 105 (1980).
5. M. Fuertes, M.T. García-López, G. García-Muñoz and R. Madroño, J. Carbohydr., Nucleosides, Nucleotides, **2**, 277 (1975).
5a. M. Fuertes, M.T. García-López, G. García-Muñoz and M. Stud, J. Org. Chem., **41**, 4074 (1976).
6. P.C. Srivastava, M.V. Pickering, L.B. Allen, D.G. Sreeter, M.T. Campbell, J.T. Witkowski, R.W. Sidwell and R.K. Robins, J. Med. Chem., **20**, 256 (1977).
7. F. G. de las Heras, R. Alonso and G. Alonso, J. Med. Chem., **22**, 496 (1979).
8. R. Zelinski and K. Yorke, J. Org. Chem., **23**, 640 (1958).
9. M.T. García-López, R. Herranz and G. Alonso, J. Heterocyclic Chem., **17**, 113 (1980).

10. M.T. García-López and R. Herranz, Eur. J. Med. Chem., **15**, 551 (1980).
11. R.I. Geran, N.H. Greenberg, M.M. Mc Donald, A.M. Schumacher and B.J. Abbot, Cancer Chemother. Rep. Part 3, **3**, 17 (1972).
12. F.G. de las Heras and P. Fernández-Resa, J. Chem. Soc. Perkin I, 903 (1982).

RECEIVED: April 8, 1982